Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: Initial experience in 134 patients-a hypothesis-generating exploratory study

Onofrio A. Catalano, Bruce R. Rosen, Dushyant V. Sahani, Peter F. Hahn, Alexander Guimaraes, Mark G. Vangel, Emanuele Nicolai, Andrea Soricelli, Marco Salvatore

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Purpose: To compare the clinical impact of combined positron emission tomography (PET) and magnetic resonance (MR) imaging to that of combined PET and computed tomography (CT) performed on the same day in patients with cancer. Materials and Methods: This HIPAA-compliant retrospective study was approved by the institutional review board. Patients gave written informed consent for study enrollment, including the possibility to use their imaging and clinical data in future evaluations. A total of 134 patients with cancer with a non-central nervous system primary neoplasm underwent same-day fluorodeoxyglucose (FDG) PET/CT and FDG PET/MR imaging. PET/CT and PET/MR studies were independently interpreted by teams of radiologists and nuclear medicine physicians. Four readers, divided into two teams composed of one radiologist and one nuclear medicine physician each, read all 134 studies. The referring physician classified discordance between PET/CT and PET/MR observations either as findings affecting clinical management or as findings not affecting clinical management. Data were compared with the χ2 test. Results: Findings affecting clinical management were noted for PET/CT studies but not for PET/MR studies in two (1.5%) of 134 patients and for PET/MR studies but not for PET/ CT studies in 24 (17.9%) of 134 patients. The discrepancies between findings affecting clinical management detected with PET/MR imaging over those detected with PET/CT were significant (P <.001). Conclusion: In these patients, PET/MR imaging alone contributed to clinical management more often than did PET/CT alone. PET/MR imaging provides information that affects the care of patients with cancer and is unavailable from PET/CT.

Original languageEnglish (US)
Pages (from-to)857-869
Number of pages13
JournalRadiology
Volume269
Issue number3
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Magnetic Resonance Imaging
Neoplasms
Magnetic Resonance Spectroscopy
Nuclear Medicine
Physicians
Nervous System Neoplasms
Health Insurance Portability and Accountability Act
Positron Emission Tomography Computed Tomography
Research Ethics Committees
Informed Consent
Patient Care
Retrospective Studies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT : Initial experience in 134 patients-a hypothesis-generating exploratory study. / Catalano, Onofrio A.; Rosen, Bruce R.; Sahani, Dushyant V.; Hahn, Peter F.; Guimaraes, Alexander; Vangel, Mark G.; Nicolai, Emanuele; Soricelli, Andrea; Salvatore, Marco.

In: Radiology, Vol. 269, No. 3, 12.2013, p. 857-869.

Research output: Contribution to journalArticle

Catalano, Onofrio A. ; Rosen, Bruce R. ; Sahani, Dushyant V. ; Hahn, Peter F. ; Guimaraes, Alexander ; Vangel, Mark G. ; Nicolai, Emanuele ; Soricelli, Andrea ; Salvatore, Marco. / Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT : Initial experience in 134 patients-a hypothesis-generating exploratory study. In: Radiology. 2013 ; Vol. 269, No. 3. pp. 857-869.
@article{7cfc61b7ab8241f6be3b389cc32a02df,
title = "Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: Initial experience in 134 patients-a hypothesis-generating exploratory study",
abstract = "Purpose: To compare the clinical impact of combined positron emission tomography (PET) and magnetic resonance (MR) imaging to that of combined PET and computed tomography (CT) performed on the same day in patients with cancer. Materials and Methods: This HIPAA-compliant retrospective study was approved by the institutional review board. Patients gave written informed consent for study enrollment, including the possibility to use their imaging and clinical data in future evaluations. A total of 134 patients with cancer with a non-central nervous system primary neoplasm underwent same-day fluorodeoxyglucose (FDG) PET/CT and FDG PET/MR imaging. PET/CT and PET/MR studies were independently interpreted by teams of radiologists and nuclear medicine physicians. Four readers, divided into two teams composed of one radiologist and one nuclear medicine physician each, read all 134 studies. The referring physician classified discordance between PET/CT and PET/MR observations either as findings affecting clinical management or as findings not affecting clinical management. Data were compared with the χ2 test. Results: Findings affecting clinical management were noted for PET/CT studies but not for PET/MR studies in two (1.5{\%}) of 134 patients and for PET/MR studies but not for PET/ CT studies in 24 (17.9{\%}) of 134 patients. The discrepancies between findings affecting clinical management detected with PET/MR imaging over those detected with PET/CT were significant (P <.001). Conclusion: In these patients, PET/MR imaging alone contributed to clinical management more often than did PET/CT alone. PET/MR imaging provides information that affects the care of patients with cancer and is unavailable from PET/CT.",
author = "Catalano, {Onofrio A.} and Rosen, {Bruce R.} and Sahani, {Dushyant V.} and Hahn, {Peter F.} and Alexander Guimaraes and Vangel, {Mark G.} and Emanuele Nicolai and Andrea Soricelli and Marco Salvatore",
year = "2013",
month = "12",
doi = "10.1148/radiol.13131306",
language = "English (US)",
volume = "269",
pages = "857--869",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT

T2 - Initial experience in 134 patients-a hypothesis-generating exploratory study

AU - Catalano, Onofrio A.

AU - Rosen, Bruce R.

AU - Sahani, Dushyant V.

AU - Hahn, Peter F.

AU - Guimaraes, Alexander

AU - Vangel, Mark G.

AU - Nicolai, Emanuele

AU - Soricelli, Andrea

AU - Salvatore, Marco

PY - 2013/12

Y1 - 2013/12

N2 - Purpose: To compare the clinical impact of combined positron emission tomography (PET) and magnetic resonance (MR) imaging to that of combined PET and computed tomography (CT) performed on the same day in patients with cancer. Materials and Methods: This HIPAA-compliant retrospective study was approved by the institutional review board. Patients gave written informed consent for study enrollment, including the possibility to use their imaging and clinical data in future evaluations. A total of 134 patients with cancer with a non-central nervous system primary neoplasm underwent same-day fluorodeoxyglucose (FDG) PET/CT and FDG PET/MR imaging. PET/CT and PET/MR studies were independently interpreted by teams of radiologists and nuclear medicine physicians. Four readers, divided into two teams composed of one radiologist and one nuclear medicine physician each, read all 134 studies. The referring physician classified discordance between PET/CT and PET/MR observations either as findings affecting clinical management or as findings not affecting clinical management. Data were compared with the χ2 test. Results: Findings affecting clinical management were noted for PET/CT studies but not for PET/MR studies in two (1.5%) of 134 patients and for PET/MR studies but not for PET/ CT studies in 24 (17.9%) of 134 patients. The discrepancies between findings affecting clinical management detected with PET/MR imaging over those detected with PET/CT were significant (P <.001). Conclusion: In these patients, PET/MR imaging alone contributed to clinical management more often than did PET/CT alone. PET/MR imaging provides information that affects the care of patients with cancer and is unavailable from PET/CT.

AB - Purpose: To compare the clinical impact of combined positron emission tomography (PET) and magnetic resonance (MR) imaging to that of combined PET and computed tomography (CT) performed on the same day in patients with cancer. Materials and Methods: This HIPAA-compliant retrospective study was approved by the institutional review board. Patients gave written informed consent for study enrollment, including the possibility to use their imaging and clinical data in future evaluations. A total of 134 patients with cancer with a non-central nervous system primary neoplasm underwent same-day fluorodeoxyglucose (FDG) PET/CT and FDG PET/MR imaging. PET/CT and PET/MR studies were independently interpreted by teams of radiologists and nuclear medicine physicians. Four readers, divided into two teams composed of one radiologist and one nuclear medicine physician each, read all 134 studies. The referring physician classified discordance between PET/CT and PET/MR observations either as findings affecting clinical management or as findings not affecting clinical management. Data were compared with the χ2 test. Results: Findings affecting clinical management were noted for PET/CT studies but not for PET/MR studies in two (1.5%) of 134 patients and for PET/MR studies but not for PET/ CT studies in 24 (17.9%) of 134 patients. The discrepancies between findings affecting clinical management detected with PET/MR imaging over those detected with PET/CT were significant (P <.001). Conclusion: In these patients, PET/MR imaging alone contributed to clinical management more often than did PET/CT alone. PET/MR imaging provides information that affects the care of patients with cancer and is unavailable from PET/CT.

UR - http://www.scopus.com/inward/record.url?scp=84890038096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890038096&partnerID=8YFLogxK

U2 - 10.1148/radiol.13131306

DO - 10.1148/radiol.13131306

M3 - Article

C2 - 24009348

AN - SCOPUS:84890038096

VL - 269

SP - 857

EP - 869

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -